Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder

키워드

참고문헌 (22)

1. Bandelow B, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision", World J Biol Psychiatry, 9, pp.248~312 (2008)
2. Pallanti S, "Treatment-refractory obsessive-compulsive disorder : Methodological issues, operational definitions and therapeutic lines", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.400~412 (2006)
3. Stein DJ, "A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder", Curr Psychiatry Rep, 14, pp.211~219 (2012)
4. Bruno A, "Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder : A double-blind, placebo-controlled study", J Psychopharmacol, 26, pp.1456~1462 (2012)
5. Khalkhali M, "Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder : A randomized controlled trial", Iran J Psychiatry, 11, pp.104~114 (2016)
6. Aouizerate B, "Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder", Neuropsychiatr Dis Treat, 1, pp.231~243 (2005)
7. IPT SPECT before and after treatment with serotonin reuptake inhibitors, "Neuropsychobiology", 2007, 156~162
8. Pittenger C, "Glutamate abnormalities in obsessive compulsive disorder : Neurobiology, pathophysiology, and treatment", Pharmacol Ther, 132, pp.314~332 (2011)
9. Leach MJ, "Neurochemical and behavioral aspects of lamotrigine", Epilepsia, 32(Suppl 2), pp.S4~S8 (1991)
10. Mamo D, "Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia : A triple tracer PET study", Am J Psychiatry, 164, pp.1411~1417 (2007)
11. Westenberg HG, "Neurobiology of obsessive-compulsive disorder : Serotonin and beyond", CNS Spectr, 12(Suppl 3), pp.14~27 (2007)
12. Zhou DD, "Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder : A network meta-analysis", Prog Neuropsychopharmacol Biol Psychiatry, 90, pp.277~287 (2019)
13. Beaulieu AM, "The psychopharmacology algorithm project at the Harvard South Shore Program : An algorithm for adults with obsessive-compulsive disorder", Psychiatry Res, 281, pp.112583~ (2019)
14. Zohar J, "Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment", Arch Gen Psychiatry, 45, pp.167~172 (1988)
15. Browne M, "The benefits of clomipraminefluoxetine combination in obsessive compulsive disorder", Can J Psychiatry, 38, pp.242~243 (1993)
16. Diniz JB, "A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder", J Clin Psychopharmacol, 31, pp.763~768 (2011)
17. Andrade C, "Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder : Benefits and risks", J Clin Psychiatry, 74, pp.e1128~e1133 (2013)
18. Sternbach H, "Fluoxetine-clomipramine interaction", J Clin Psychiatry, 56, pp.171~172 (1995)
19. Figueroa Y, "Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents", J Child Adolesc Psychopharmacol, 8, pp.61~67 (1998)
20. Szegedi A, "Combination treatment with clomipramine and fluvoxamine : Drug monitoring, safety, and tolerability data", J Clin Psychiatry, 57, pp.257~264 (1996)
21. Han C, "Management of chronic depressive patients with residual symptoms", CNS Drugs, 27(Suppl 1), pp.S53~S57 (2013)
22. Cheolmin Shin, "Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 19(2), pp.243~253 (2021), 대한정신약물학회[DOI]

관련 논문AI추천